A shortage listing ends. 16 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 4 of 170 of this archive, newest first.
The document is four pages. Three of them are about dates.
The observation that closes a facility is rarely the dramatic one.
A plateau at an intermediate dose and a plateau at the maximum dose look identical from the outside and mean different things.
The Journal does not treat a badge as evidence and states so wherever it reports one.
A needle blunts on first use. Reuse is uncomfortable, and it is a documented contributor to lipohypertrophy.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
Reported from the sessions, and from the two hours afterwards.
The route did not close because of a rule about peptides.
Asymptomatic pancreatic enzyme elevation is common on treatment and is not pancreatitis. The distinction is clinical, not biochemical.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Reported from the analysis, not from a warning notice.
The observation that closes a facility is rarely the dramatic one.
The evidence base is thin and the document says so, which is to its credit.
Two withdrawal-design trials tell us what happens when treatment stops. Neither tells us what the lowest effective maintenance dose is.
A document is only as good as the chain that connects it to the material, and most chains here are two or three links longer than the paperwork admits.
The evidence base is thin and the document says so, which is to its credit.
A proper account of an operation that existed, and of what closing it cost.
A proper account of an operation that existed, and of what closing it cost.
The route did not close because of a rule about peptides.
Calibration drift is real, unremarkable, and the reason serious laboratories run internal standards.
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.
Every instrument specification quoted in an advertisement is a best case obtained on a calibration mixture, not on a submitted vial.
A proper account of an operation that existed, and of what closing it cost.
Efficacy was never the question in this appraisal. Duration of treatment was.
Follow the resin, not the catalogue.
The trials studied planned withdrawal. Almost nobody stops that way.
The observation that closes a facility is rarely the dramatic one.
Efficacy was never the question in this appraisal. Duration of treatment was.
A design note rather than a result: what the comparator was, and what that permits you to conclude.